

**Eltrombopag (as Eltrombopag olamine) 50 mg** Revolade 50mg tablets | 28 tablet [PoM](#) £1,540.00 DT = £1,540.00

**Eltrombopag (as Eltrombopag olamine) 75 mg** Revolade 75mg tablets | 28 tablet [PoM](#) £2,310.00 DT = £2,310.00

## Romiplostim

28-Jan-2019

- **DRUG ACTION** Romiplostim is an Fc- $\gamma$  peptide fusion protein that binds to and activates the thrombopoietin (TPO) receptor, thereby increasing platelet production.

### ● INDICATIONS AND DOSE

**Chronic immune (idiopathic) thrombocytopenic purpura in patients refractory to other treatments (such as corticosteroids or immunoglobulins) (under expert supervision)**

#### ► BY SUBCUTANEOUS INJECTION

- Child 1-17 years: Initially 1 microgram/kg once weekly, adjusted in steps of 1 microgram/kg once weekly (max. per dose 10 micrograms/kg once weekly) until a stable platelet count of  $50 \times 10^9$ /litre or more is reached, consult product literature for further details of dose adjustments; reassess bodyweight every 12 weeks, discontinue treatment if inadequate response after 4 weeks at maximum dose

- **CAUTIONS** Risk factors for thromboembolism
- **SIDE-EFFECTS**
  - **Common or very common** Anaemia · angioedema · arthralgia · asthenia · bone marrow disorders · chills · constipation · cough · diarrhoea · dizziness · embolism and thrombosis · eye inflammation · fever · flushing · gastrointestinal discomfort · headaches · hypersensitivity · increased risk of infection · influenza like illness · muscle complaints · nausea · oropharyngeal pain · pain · palpitations · peripheral oedema · peripheral swelling · sensation abnormal · skin reactions · sleep disorders
  - **Uncommon** Alopecia · appetite decreased · chest pain · clonus · dehydration · depression · dry throat · dysphagia · dyspnoea · erythromelalgia · eye disorders · eye pruritus · feeling hot · feeling jittery · gastroesophageal reflux disease · gout · haemorrhage · hair growth abnormal · hypotension · irritability · leucocytosis · malaise · muscle weakness · myocardial infarction · nasal complaints · neoplasms · oral disorders · peripheral ischaemia · peripheral neuropathy · photosensitivity reaction · pleuritic pain · portal vein thrombosis · skin nodule · splenomegaly · taste altered · thrombocytosis · tooth discolouration · vertigo · vision disorders · vomiting · weight changes
- **PREGNANCY** Manufacturer advises avoid—toxicity in animal studies.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution; consider avoiding in moderate to severe impairment (risk of thromboembolic complications).
- **RENAL IMPAIRMENT** Manufacturer advises caution—no information available.
- **MONITORING REQUIREMENTS**
  - Manufacturer advises monitor full blood count and peripheral blood smears for morphological abnormalities before and during treatment.
  - Manufacturer advises monitor platelet count weekly until platelet count reaches  $50 \times 10^9$ /litre or more for at least 4 weeks without dose adjustment, then monthly thereafter.
  - Manufacturer advises monitor platelet count following treatment discontinuation—risk of bleeding.

### ● PATIENT AND CARER ADVICE

**Driving and skilled tasks** Manufacturer advises that patients and their carers should be counselled on the effects on driving and the performance of skilled tasks—increased risk of dizziness.

### ● NATIONAL FUNDING/ACCESS DECISIONS

#### Scottish Medicines Consortium (SMC) decisions

SMC No. SMC2126

The *Scottish Medicines Consortium* has advised (February 2019) that romiplostim (*Nplate*<sup>®</sup>) is accepted for restricted use within NHS Scotland for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients aged one year and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Romiplostim is restricted to those with severe symptomatic ITP or those with a high risk of bleeding.

#### All Wales Medicines Strategy Group (AWMSG) decisions

AWMSG No. 3103

The *All Wales Medicines Strategy Group* has advised (March 2019) that romiplostim (*Nplate*<sup>®</sup>) is recommended as an option for use within NHS Wales for the treatment of chronic immune (idiopathic) thrombocytopenic purpura in patients from 1 year of age up to 18 years of age who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

#### Powder for solution for injection

##### ► *Nplate* (Amgen Ltd)

**Romiplostim 125 microgram** *Nplate* 125microgram powder for solution for injection vials | 1 vial [PoM](#) £241.00

# Nutrition and metabolic disorders

## 1 Acid-base imbalance

### 1.1 Metabolic acidosis

#### ALKALISING DRUGS

### Trometamol

(Tris(hydroxymethyl)aminomethane, THAM)

#### ● INDICATIONS AND DOSE

##### Metabolic acidosis

###### ► BY INTRAVENOUS INFUSION

- Child: To be administered at an amount appropriate to the body base deficit

- **UNLICENSED USE** Unlicensed preparation.
- **CONTRA-INDICATIONS** Anuria · chronic respiratory acidosis
- **CAUTIONS** Extravasation can cause severe tissue damage
- **SIDE-EFFECTS** Hepatic necrosis (following administration via umbilical vein) (in neonates) · hyperkalaemia (in renal impairment) · hypoglycaemia · respiratory depression
- SIDE-EFFECTS, FURTHER INFORMATION** Respiratory support may be required because trometamol induces respiratory depression.
- **PREGNANCY** Limited information available, hypoglycaemia may harm fetus.
- **BREAST FEEDING** No information available.